COMPASS Pathways (NASDAQ:CMPS) Raised to “Strong-Buy” at Lifesci Capital

COMPASS Pathways (NASDAQ:CMPS) was upgraded by equities research analysts at Lifesci Capital to a “strong-buy” rating in a research note issued to investors on Thursday,Zacks.com reports.

Several other analysts have also recently weighed in on CMPS. Compass Point set a $15.00 price target on shares of COMPASS Pathways in a report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of COMPASS Pathways in a research note on Wednesday, January 21st. Royal Bank Of Canada boosted their price target on shares of COMPASS Pathways from $16.00 to $21.00 and gave the company an “outperform” rating in a research report on Friday, January 23rd. Finally, Morgan Stanley raised their price objective on shares of COMPASS Pathways from $10.00 to $11.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.11.

COMPASS Pathways Trading Down 0.7%

NASDAQ CMPS opened at $5.81 on Thursday. The stock has a market cap of $557.88 million, a P/E ratio of -2.14 and a beta of 1.92. COMPASS Pathways has a fifty-two week low of $2.25 and a fifty-two week high of $8.20. The stock has a 50 day simple moving average of $6.75 and a two-hundred day simple moving average of $5.83. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.23 and a current ratio of 1.23.

Institutional Investors Weigh In On COMPASS Pathways

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Advisory Services Network LLC purchased a new position in shares of COMPASS Pathways during the third quarter valued at approximately $41,000. BIT Capital GmbH bought a new position in COMPASS Pathways during the 3rd quarter valued at approximately $54,000. Raymond James Financial Inc. increased its position in COMPASS Pathways by 82.7% during the 3rd quarter. Raymond James Financial Inc. now owns 13,763 shares of the company’s stock valued at $79,000 after buying an additional 6,228 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new position in COMPASS Pathways during the fourth quarter valued at $96,000. Finally, U.S. Capital Wealth Advisors LLC bought a new stake in COMPASS Pathways in the fourth quarter worth $104,000. Hedge funds and other institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, COMPASS Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.